| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers (NCT02244203) | Boehringer Ingelheim | 2009-02-01 |
| Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease (NCT00975195) | Boehringer Ingelheim | 2009-02-01 |
| Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus (NCT00877929) | Boehringer Ingelheim | 2009-02-01 |
| Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I (NCT00793624) | Boehringer Ingelheim | 2009-02-01 |
| Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects (NCT02171598) | Boehringer Ingelheim | 2009-02-01 |
| Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery (NCT00846807) | Boehringer Ingelheim | 2009-02-01 |
| Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery (NCT00967447) | Boehringer Ingelheim | 2009-02-01 |
| BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD (NCT00846768) | Boehringer Ingelheim | 2009-02-01 |
| 12 / 48 wk Pivotal PFT vs PBO in COPD II (NCT00782509) | Boehringer Ingelheim | 2009-02-01 |
| Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects (NCT02183571) | Boehringer Ingelheim | 2009-02-01 |
| Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder (NCT00844194) | Boehringer Ingelheim | 2009-02-01 |
| 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab (NCT00826267) | Boehringer Ingelheim | 2009-01-01 |
| Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II (NCT00796653) | Boehringer Ingelheim | 2009-01-01 |
| Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects (NCT02191709) | Boehringer Ingelheim | 2009-01-01 |
| BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers (NCT02171715) | Boehringer Ingelheim | 2009-01-01 |
| Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD (NCT00824382) | Boehringer Ingelheim | 2009-01-01 |
| Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers (NCT02172248) | Boehringer Ingelheim | 2009-01-01 |
| Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers (NCT02215759) | Boehringer Ingelheim | 2009-01-01 |
| Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention (NCT00818753) | Boehringer Ingelheim | 2009-01-01 |
| LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer (NCT00805194) | Boehringer Ingelheim | 2008-12-03 |
| Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers (NCT02261064) | Boehringer Ingelheim | 2008-12-01 |
| Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive (NCT00800683) | Boehringer Ingelheim | 2008-12-01 |
| Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug (NCT00819091) | Boehringer Ingelheim | 2008-12-01 |
| Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients (NCT00819052) | Boehringer Ingelheim | 2008-12-01 |
| BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients (NCT00796549) | Boehringer Ingelheim | 2008-12-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis (NCT00848055) | Boehringer Ingelheim | 2008-12-01 |
| Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC (NCT00806819) | Boehringer Ingelheim | 2008-12-01 |
| 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma (NCT00818454) | Boehringer Ingelheim | 2008-12-01 |
| Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design (NCT00798161) | Boehringer Ingelheim | 2008-12-01 |
| Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia (NCT00804856) | Boehringer Ingelheim | 2008-11-27 |
| 12 / 48 Week Pivotal PFT vs PBO in COPD I (NCT00782210) | Boehringer Ingelheim | 2008-11-01 |
| Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers (NCT02183181) | Boehringer Ingelheim | 2008-11-01 |
| RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial (NCT00808067) | Boehringer Ingelheim | 2008-11-01 |
| Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort (NCT02242305) | Boehringer Ingelheim | 2008-11-01 |
| Phase I Study of BI 831266 in Patients With Advanced Solid Tumours (NCT00756223) | Boehringer Ingelheim | 2008-11-01 |
| Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (NCT02217644) | Boehringer Ingelheim | 2008-11-01 |
| Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease (NCT00752388) | Boehringer Ingelheim | 2008-11-01 |
| Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers (NCT02194257) | Boehringer Ingelheim | 2008-10-01 |
| Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects (NCT02183493) | Boehringer Ingelheim | 2008-10-01 |
| Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II) (NCT00776984) | Boehringer Ingelheim | 2008-10-01 |
| Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) (NCT00774397) | Boehringer Ingelheim | 2008-10-01 |
| Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. (NCT00748709) | Boehringer Ingelheim | 2008-10-01 |
| Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I) (NCT00772538) | Boehringer Ingelheim | 2008-10-01 |
| 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients (NCT00789035) | Boehringer Ingelheim | 2008-10-01 |
| Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers (NCT02211950) | Boehringer Ingelheim | 2008-10-01 |
| Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks (NCT00743015) | Boehringer Ingelheim | 2008-09-01 |
| PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice. (NCT00736502) | Boehringer Ingelheim | 2008-09-01 |
| Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers (NCT02261129) | Boehringer Ingelheim | 2008-09-01 |
| Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers (NCT02215772) | Boehringer Ingelheim | 2008-09-01 |
| Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (NCT02264184) | Boehringer Ingelheim | 2008-09-01 |
| Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis (NCT00737100) | Boehringer Ingelheim | 2008-09-01 |
| Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers (NCT02215031) | Boehringer Ingelheim | 2008-09-01 |
| Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan (NCT01108796) | Boehringer Ingelheim | 2008-09-01 |
| Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers (NCT02171494) | Boehringer Ingelheim | 2008-09-01 |
| BI 44370 TA in Acute Migraine Attack (NCT00751803) | Boehringer Ingelheim | 2008-08-01 |
| A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate (NCT00740051) | Boehringer Ingelheim | 2008-08-01 |
| Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM (NCT00736099) | Boehringer Ingelheim | 2008-08-01 |
| Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis (NCT00726479) | Boehringer Ingelheim | 2008-08-01 |
| Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers (NCT02171559) | Boehringer Ingelheim | 2008-08-01 |
| BI 10773 add-on to Metformin in Patients With Type 2 Diabetes (NCT00749190) | Boehringer Ingelheim | 2008-08-01 |
| BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma (NCT00727506) | Boehringer Ingelheim | 2008-07-14 |
| Pramipexole ER vs. Placebo in Fibromyalgia (NCT00689052) | Boehringer Ingelheim | 2008-07-01 |
| Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT00720499) | Boehringer Ingelheim | 2008-07-01 |
| Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours (NCT00716417) | Boehringer Ingelheim | 2008-07-01 |
| Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects (NCT02175394) | Boehringer Ingelheim | 2008-07-01 |
| Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers (NCT02276391) | Boehringer Ingelheim | 2008-07-01 |
| Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects (NCT02183376) | Boehringer Ingelheim | 2008-07-01 |
| The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients (NCT00716092) | Boehringer Ingelheim | 2008-07-01 |
| Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers (NCT02276378) | Boehringer Ingelheim | 2008-07-01 |
| Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers (NCT02183402) | Boehringer Ingelheim | 2008-06-01 |
| Observational Non-Interventional Study With Spiriva Respimat in COPD Patients (NCT00699699) | Boehringer Ingelheim | 2008-06-01 |
| Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers (NCT02182453) | Boehringer Ingelheim | 2008-06-01 |
| Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects (NCT02182310) | Boehringer Ingelheim | 2008-06-01 |
| Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (NCT00696020) | Boehringer Ingelheim | 2008-06-01 |
| Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers (NCT02182336) | Boehringer Ingelheim | 2008-06-01 |
| Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients (NCT00730925) | Boehringer Ingelheim | 2008-06-01 |
| Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort (NCT00805857) | Boehringer Ingelheim | 2008-06-01 |
| Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers (NCT02171533) | Boehringer Ingelheim | 2008-06-01 |
| BI 10773 Administered as Oral Solution to Healthy Male Volunteers (NCT02172274) | Boehringer Ingelheim | 2008-06-01 |
| Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers (NCT02221375) | Boehringer Ingelheim | 2008-06-01 |
| Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers (NCT02171585) | Boehringer Ingelheim | 2008-06-01 |
| Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) (NCT02231177) | Boehringer Ingelheim | 2008-06-01 |
| Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis (NCT01909778) | Boehringer Ingelheim | 2008-06-01 |
| BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment (NCT00632749) | Boehringer Ingelheim | 2008-05-01 |
| Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers (NCT02171481) | Boehringer Ingelheim | 2008-05-01 |
| Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers (NCT02183389) | Boehringer Ingelheim | 2008-05-01 |
| Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers (NCT02183428) | Boehringer Ingelheim | 2008-05-01 |
| Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (NCT02171520) | Boehringer Ingelheim | 2008-05-01 |
| Tiotropium and Salmeterol PK Study in COPD Patients (NCT00673478) | Boehringer Ingelheim | 2008-05-01 |
| Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome (NCT00681863) | Boehringer Ingelheim | 2008-05-01 |
| Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD (NCT00662792) | Boehringer Ingelheim | 2008-04-15 |
| Tiotropium/Salmeterol Inhalation Powder in COPD (NCT00668772) | Boehringer Ingelheim | 2008-04-15 |
| Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) (NCT00662740) | Boehringer Ingelheim | 2008-04-15 |
| Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers (NCT02244190) | Boehringer Ingelheim | 2008-04-01 |
| Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers (NCT02183441) | Boehringer Ingelheim | 2008-04-01 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers (NCT02254109) | Boehringer Ingelheim | 2008-04-01 |
| Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (NCT00680186) | Boehringer Ingelheim | 2008-04-01 |
| LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (NCT00711594) | Boehringer Ingelheim | 2008-04-01 |
| BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) (NCT00656136) | Boehringer Ingelheim | 2008-04-01 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function (NCT02191228) | Boehringer Ingelheim | 2008-04-01 |